Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adverse Event Surveillance Pilot From AHRQ Examines Hypertension, Diabetes

Executive Summary

A study recently initiated by the Agency for Healthcare Research and Quality will develop a distributed network prototype by aggregating medical records and claims data for diabetes and hypertension therapy

You may also be interested in...



Avandia Meta-Analysis Problems Metastasize For FDA After JAMA Studies

GlaxoSmithKline's Avandia (rosiglitazone) has become the chorus line to discussions of FDA's drug approval and oversight systems

IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns

The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.

NSF's Cosmetics Verification Program Fizzles, While EWG's Could See Second Boom

NSF International has put its cosmetic product verification program on ice due to lack of interest since its launch in April 2017. Meanwhile, more than 1,000 products from 75+ brands have earned the "EWG Verified" mark, and the NGO says interest is higher than ever following Walmart's announcement in September that it will begin pushing vendors to pursue the verification.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel